Fujian Cosunter Pharmaceutical Co Ltd 300436.SZ

Last Updated: May 15, 12:00 AM·SZSE

Fujian Cosunter Pharmaceutical Co Ltd

Fujian Cosunter Pharmaceutical Co Ltd. Stock Analysis 300436.SZ

China Health Care Mid Cap
Fujian Cosunter Pharmaceutical Co., Ltd. engages in medical research and development and the manufacturing and sale of pharmaceutical drugs. The company is headquartered in Fuzhou, Fujian. The company went IPO on 2015-04-23. The firm's main products include Tenofovir alafenamide Fumarate Tablets, Entecavir Capsules, Lamivudine Tablets, Silybin Meglumine Tablets, Adefovir Dipivoxil Tablets, Ursodeoxycholic Acid Capsules, Tadalafil Tablets, Rivaroxaban Tablets and others. The firm's products are mainly used in the fields of anti-hepatitis B virus, liver health, men's health, cardiovascular treatment and others. The firm mainly operates its businesses in the domestic market.
Read More
Lock image
crown-icon

Shariah Compliance Report

An extensive business and financial screening of the company which specifies why a stock is halal or haram!

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.